| KO |
Report |
Comparable EPS (Q2 2026) |
BEAT |
pred ~$0.95 vs. cons $0.933 |
HIGH |
| KO |
Report |
Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~4.0% vs. cons 3.49% |
MEDIUM |
| KO |
Report |
Total Volume Growth (Q2 2026) |
BEAT |
pred ~1.2% vs. cons 0.74% |
MEDIUM |
| KO |
Guide |
Comparable EPS Growth (FY2026) |
UNCHANGED |
guide ~8-9% ($3.255 mid) vs. cons $3.268 |
MEDIUM |
| KO |
Guide |
Organic Revenue Growth (FY2026) |
LOWER |
guide ~4-5% (4.5% mid) vs. cons 4.86% |
MEDIUM |
| KO |
Guide |
Fairlife/Webster Ramp (qualitative) |
BETTER |
Confirm ramp on track; positive H2 signal vs. no prior explicit confirmation |
HIGH |
| KO |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| KO |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE - H2 implicit cuts flow through estimates as models reset to guidance midpoints below current consensus; fairlife confirmation is a partial offset but insufficient to reverse direction |
MEDIUM |